PT2496580E - Inibidor do bromodomínio da benzodiazepina - Google Patents

Inibidor do bromodomínio da benzodiazepina Download PDF

Info

Publication number
PT2496580E
PT2496580E PT107406548T PT10740654T PT2496580E PT 2496580 E PT2496580 E PT 2496580E PT 107406548 T PT107406548 T PT 107406548T PT 10740654 T PT10740654 T PT 10740654T PT 2496580 E PT2496580 E PT 2496580E
Authority
PT
Portugal
Prior art keywords
bromodomain inhibitor
benzodiazepine
benzodiazepine bromodomain
inhibitor
bromodomain
Prior art date
Application number
PT107406548T
Other languages
English (en)
Inventor
Romain Luc Marie Gosmini
Olivier Mirguet
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42667965&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2496580(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0919433A external-priority patent/GB0919433D0/en
Priority claimed from GBGB1010509.6A external-priority patent/GB201010509D0/en
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of PT2496580E publication Critical patent/PT2496580E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
PT107406548T 2009-11-05 2010-08-06 Inibidor do bromodomínio da benzodiazepina PT2496580E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0919433A GB0919433D0 (en) 2009-11-05 2009-11-05 Novel compounds
GBGB1010509.6A GB201010509D0 (en) 2010-06-22 2010-06-22 Novel compounds

Publications (1)

Publication Number Publication Date
PT2496580E true PT2496580E (pt) 2014-02-21

Family

ID=42667965

Family Applications (2)

Application Number Title Priority Date Filing Date
PT107406548T PT2496580E (pt) 2009-11-05 2010-08-06 Inibidor do bromodomínio da benzodiazepina
PT131926669T PT2722334E (pt) 2009-11-05 2010-08-06 Inibidor do bromodomínio da benzodiazepina

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT131926669T PT2722334E (pt) 2009-11-05 2010-08-06 Inibidor do bromodomínio da benzodiazepina

Country Status (32)

Country Link
US (3) US9023842B2 (pt)
EP (3) EP2496580B1 (pt)
JP (1) JP5524343B2 (pt)
KR (1) KR101424989B1 (pt)
CN (1) CN102762569B (pt)
AU (1) AU2010314395B2 (pt)
BR (1) BR112012010706A2 (pt)
CA (1) CA2779355C (pt)
CL (1) CL2012001178A1 (pt)
CO (1) CO6540003A2 (pt)
CR (1) CR20120283A (pt)
CY (2) CY1114988T1 (pt)
DK (2) DK2722334T3 (pt)
DO (1) DOP2012000114A (pt)
EA (1) EA020390B1 (pt)
ES (3) ES2446647T3 (pt)
HK (3) HK1191012A1 (pt)
HR (2) HRP20140107T1 (pt)
HU (1) HUE026421T2 (pt)
IL (2) IL219090A0 (pt)
MA (1) MA33803B1 (pt)
ME (1) ME02360B (pt)
MX (1) MX2012005295A (pt)
MY (1) MY160456A (pt)
NZ (1) NZ599258A (pt)
PE (1) PE20121181A1 (pt)
PL (2) PL2496580T3 (pt)
PT (2) PT2496580E (pt)
RS (2) RS54592B1 (pt)
SI (2) SI2496580T1 (pt)
SM (2) SMT201400024B (pt)
WO (1) WO2011054553A1 (pt)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0919432D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Use
ME02356B (me) * 2009-11-05 2016-06-20 Glaxosmithkline Llc Inhibitor bromodomena benzodiazepina
US9301962B2 (en) 2010-05-14 2016-04-05 Baylor College Of Medicine Male contraceptive compositions and methods of use
KR101857599B1 (ko) 2010-05-14 2018-05-14 다나-파버 캔서 인스티튜트 인크. 종양형성, 염증성 질환 및 다른 장애를 치료하기 위한 조성물 및 방법
WO2011143660A2 (en) 2010-05-14 2011-11-17 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating leukemia
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
WO2012075456A1 (en) 2010-12-02 2012-06-07 Constellation Pharmaceuticals Bromodomain inhibitors and uses thereof
EP2705039B1 (en) 2011-05-04 2017-07-26 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
WO2012174487A2 (en) 2011-06-17 2012-12-20 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
WO2013027168A1 (en) 2011-08-22 2013-02-28 Pfizer Inc. Novel heterocyclic compounds as bromodomain inhibitors
DE102011082013A1 (de) * 2011-09-01 2013-03-07 Bayer Pharma AG 6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine
WO2013097052A1 (en) 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
EP2838881B1 (en) 2012-04-20 2018-08-08 AbbVie Inc. Isoindolone derivatives
EP2864336B1 (en) 2012-06-06 2016-11-23 Constellation Pharmaceuticals, Inc. Benzo[b]isoxazoloazepine bromodomain inhibitors and uses thereof
TWI602820B (zh) 2012-06-06 2017-10-21 星宿藥物公司 溴域抑制劑及其用途
BR112014031068A2 (pt) 2012-06-12 2017-06-27 Abbvie Inc derivados piridinona e piridazinona
KR20150042231A (ko) * 2012-08-16 2015-04-20 글락소스미스클라인 엘엘씨 소세포폐암을 치료하기 위한 벤조디아제핀
EA201590356A1 (ru) 2012-08-16 2015-07-30 Байер Фарма Акциенгезельшафт 2,3-бензодиазепины
EP2900672B1 (de) 2012-09-28 2017-02-22 Bayer Pharma Aktiengesellschaft Bet-proteininhibitorische 5-aryl-triazolo-azepine
US9422290B2 (en) 2012-11-13 2016-08-23 Boehringer Ingelheim International Gmbh Triazolopyridazine
US9266891B2 (en) 2012-11-16 2016-02-23 Boehringer Ingelheim International Gmbh Substituted [1,2,4]triazolo[4,3-A]pyrazines that are BRD4 inhibitors
WO2014080291A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Biaryl derivatives as bromodomain inhibitors
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
JP2016507496A (ja) 2012-12-21 2016-03-10 ゼニス・エピジェネティクス・コーポレイションＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｃｏｒｐ． ブロモドメイン阻害剤としての新規複素環式化合物
US9492460B2 (en) * 2013-02-27 2016-11-15 Bristol-Myers Squibb Company Carbazole compounds useful as bromodomain inhibitors
JP2016510039A (ja) * 2013-02-28 2016-04-04 ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ ブロモドメイン阻害剤によるヒトサイトメガロウイルス感染および疾患の治療方法
MX2015012158A (es) 2013-03-11 2015-12-01 Abbvie Inc Inhibidores de bomodominio tetraciclicos fusionados.
EP2970262A1 (en) * 2013-03-11 2016-01-20 AbbVie Inc. Bromodomain inhibitors
CN105407894A (zh) 2013-03-14 2016-03-16 康威基内有限公司 用于抑制含布罗莫结构域的蛋白质的方法和组合物
CA2903357A1 (en) * 2013-03-14 2014-09-18 Glaxosmithkline Intellectual Property (No.2) Limited Furanopyridines as bromodomain lnhibitors
US9714946B2 (en) 2013-03-14 2017-07-25 Dana-Farber Cancer Institute, Inc. Bromodomain binding reagents and uses thereof
EP3581576B1 (en) 2013-03-15 2022-01-26 Incyte Holdings Corporation Tricyclic heterocycles as bet protein inhibitors for use in the treatment of a proliferative disease in combination with a janus kinase inhibitor
EP2792355A1 (en) 2013-04-17 2014-10-22 Albert-Ludwigs-Universität Freiburg Compounds for use as bromodomain inhibitors
BR112015027130A2 (pt) 2013-04-26 2018-07-24 Beigene Ltd 5-(3,5-dimetilisoxazol-4-il)indolin-2-ona substituído
HUE049469T2 (hu) 2013-06-21 2020-09-28 Zenith Epigenetics Ltd Új biciklusos bromodomén inhibitorok
EP3010918B1 (en) 2013-06-21 2018-08-15 Zenith Epigenetics Ltd. Novel substituted bicyclic compounds as bromodomain inhibitors
AR096758A1 (es) * 2013-06-28 2016-02-03 Abbvie Inc Inhibidores cristalinos de bromodominios
EP3019502B1 (en) 2013-07-08 2017-05-17 Incyte Holdings Corporation Tricyclic heterocycles as bet protein inhibitors
BR112016001457A2 (pt) 2013-07-25 2017-08-29 Dana Farber Cancer Inst Inc Inibidores de fatores de transcrição e usos dos mesmos
KR20160038008A (ko) 2013-07-31 2016-04-06 제니쓰 에피제네틱스 코포레이션 브로모도메인 억제제로서 신규 퀴나졸리논
US9428513B2 (en) 2013-11-07 2016-08-30 Boehringer Ingelheim International Gmbh Triazolopyrazine
US11446309B2 (en) 2013-11-08 2022-09-20 Dana-Farber Cancer Institute, Inc. Combination therapy for cancer using bromodomain and extra-terminal (BET) protein inhibitors
WO2015081189A1 (en) 2013-11-26 2015-06-04 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
US9399640B2 (en) 2013-11-26 2016-07-26 Incyte Corporation Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
GB201320994D0 (en) * 2013-11-28 2014-01-15 Univ Dundee Enzyme function probes
US9309246B2 (en) 2013-12-19 2016-04-12 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
US9695172B2 (en) 2014-01-31 2017-07-04 Dana-Farber Cancer Institute, Inc. Diazepane derivatives and uses thereof
JP2017504653A (ja) 2014-01-31 2017-02-09 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド ジアミノピリミジンベンゼンスルホン誘導体およびその使用
JP2017504651A (ja) 2014-01-31 2017-02-09 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド ジアゼパン誘導体の使用
JP6526060B2 (ja) * 2014-02-10 2019-06-05 コンサート ファーマシューティカルズ インコーポレイテッド 置換トリアゾロベンゾジアゼピン
EP3104845A4 (en) * 2014-02-10 2017-09-27 Salk Institute for Biological Studies Increasing storage of vitamin a, vitamin d and/or lipids
WO2015121230A1 (de) * 2014-02-14 2015-08-20 Bayer Pharma Aktiengesellschaft 9-substituierte 2,3-benzodiazepine
US10925881B2 (en) 2014-02-28 2021-02-23 Tensha Therapeutics, Inc. Treatment of conditions associated with hyperinsulinaemia
DK3129378T3 (da) 2014-04-09 2019-10-07 Kainos Medicine Inc Bromdomæne-hæmmende forbindelser og farmaceutisk sammensætning omfattende disse til forebyggelse eller behandling af en cancer
CN106414442B (zh) 2014-04-23 2019-03-15 因赛特公司 作为BET蛋白抑制剂的1H-吡咯并[2,3-c]吡啶-7(6H)-酮和吡唑并[3,4-c]吡啶-7(6H)-酮
ES2725928T3 (es) 2014-06-20 2019-09-30 Constellation Pharmaceuticals Inc Formas cristalinas de 2-((4S)-6-(4-clorofenil)-1-metil-4H-benzo[c]isoxazolo[4,5-e]azepin-4-il)acetamida
NO2719005T3 (pt) 2014-07-28 2018-01-20
DK3174868T3 (da) * 2014-08-01 2021-11-08 Nuevolution As Forbindelser, der er aktive mod bromodomæner
WO2016022902A1 (en) 2014-08-08 2016-02-11 Dana-Farber Cancer Institute, Inc. Diazepane derivatives and uses thereof
CA2955077A1 (en) 2014-08-08 2016-02-11 Dana-Farber Cancer Institute, Inc. Dihydropteridinone derivatives and uses thereof
US9527864B2 (en) 2014-09-15 2016-12-27 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
EP3201199A1 (en) * 2014-10-02 2017-08-09 Glaxosmithkline Intellectual Property (No. 2) Limited Compound
AU2015339511B2 (en) 2014-10-27 2020-05-14 Tensha Therapeutics, Inc. Bromodomain inhibitors
CA2966303A1 (en) 2014-12-01 2016-06-09 Zenith Epigenetics Ltd. Substituted pyridines as bromodomain inhibitors
US10710992B2 (en) 2014-12-01 2020-07-14 Zenith Epigenetics Ltd. Substituted pyridinones as bromodomain inhibitors
WO2016090219A1 (en) * 2014-12-05 2016-06-09 H. Lee Moffitt Cancer Center And Research Institute, Inc. Bromodomain inhibitor as adjuvant in cancer immunotherapy
US10292968B2 (en) 2014-12-11 2019-05-21 Zenith Epigenetics Ltd. Substituted heterocycles as bromodomain inhibitors
JP2017538721A (ja) 2014-12-17 2017-12-28 ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｌｔｄ． ブロモドメインの阻害剤
US10259809B2 (en) 2015-02-03 2019-04-16 Trillium Therapeutics Inc. Fluorinated imidazo[4,5-C]quinoline derivatives as inhibitors of bromodomain containing proteins
GB201504694D0 (en) 2015-03-19 2015-05-06 Glaxosmithkline Ip Dev Ltd Covalent conjugates
EP3307728A4 (en) 2015-06-12 2019-07-17 Dana Farber Cancer Institute, Inc. ASSOCIATION THERAPY USING TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS
EP3314005A1 (en) 2015-06-26 2018-05-02 Tensha Therapeutics, Inc. Treatment of nut midline carcinoma
JP6765622B2 (ja) 2015-07-17 2020-10-07 日本光電工業株式会社 救命支援装置
KR20180051576A (ko) 2015-09-11 2018-05-16 다나-파버 캔서 인스티튜트 인크. 아세트아미드 티에노트리아졸로디아제핀 및 그의 용도
RU2750164C2 (ru) 2015-09-11 2021-06-22 Дана-Фарбер Кэнсер Инститьют, Инк. Цианотиенотриазолодиазепины и пути их применения
WO2017059319A2 (en) * 2015-10-02 2017-04-06 Dana-Farber Cancer Institute, Inc. Combination therapy of bromodomain inhibitors and checkpoint blockade
TW201722966A (zh) 2015-10-29 2017-07-01 英塞特公司 Bet蛋白質抑制劑之非晶固體形式
WO2017091673A2 (en) 2015-11-25 2017-06-01 Dana-Farber Cancer Institute, Inc. Bivalent bromodomain inhibtors and uses thereof
AU2017251537B2 (en) 2016-04-15 2020-10-08 Abbvie Inc. Bromodomain inhibitors
FI3472157T3 (fi) 2016-06-20 2023-06-01 Incyte Corp Bet-inhibiittorin kiteisiä kiinteitä muotoja
WO2018022802A1 (en) 2016-07-26 2018-02-01 University Of Southern California Selective bromodomain inhibition of fungal bdf1
AU2017357329A1 (en) 2016-11-10 2019-06-13 Luoxin Pharmaceutical (Shanghai) Co., Ltd. Nitrogenous macrocyclic compound, preparation method therefor, pharmaceutical composition and application thereof
WO2019055579A1 (en) 2017-09-12 2019-03-21 Tolero Pharmaceuticals, Inc. TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR
CN107759607B (zh) * 2017-11-29 2019-08-23 上海万巷制药有限公司 具有抗肿瘤活性的三氮唑并二氮卓化合物及其制备方法
MX2021006544A (es) 2018-12-04 2021-07-07 Sumitomo Pharma Oncology Inc Inhibidores de cinasa dependiente de ciclina 9 (cdk9) y polimorfos de los mismos para uso como agentes para el tratamiento de cancer.
WO2020191326A1 (en) 2019-03-20 2020-09-24 Sumitomo Dainippon Pharma Oncology, Inc. Treatment of acute myeloid leukemia (aml) with venetoclax failure
GB201905721D0 (en) 2019-04-24 2019-06-05 Univ Dundee Compounds
WO2021175432A1 (en) 2020-03-04 2021-09-10 Boehringer Ingelheim International Gmbh Method for administration of an anti cancer agent
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
TW202219056A (zh) 2020-06-23 2022-05-16 美商建南德克公司 巨環化合物及其使用方法
GB202016977D0 (en) 2020-10-26 2020-12-09 In4Derm Ltd Compounds
WO2022116968A1 (zh) 2020-12-01 2022-06-09 成都苑东生物制药股份有限公司 一种新型n-杂环bet溴结构域抑制剂、其制备方法及医药用途
GB2621505A (en) 2021-06-29 2024-02-14 Tay Therapeutics Ltd Pyrrolopyridone derivatives useful in the treatment of cancer
WO2023205251A1 (en) 2022-04-19 2023-10-26 Nuevolution A/S Compounds active towards bromodomains
WO2024018423A1 (en) 2022-07-21 2024-01-25 Tay Therapeutics Limited Pyrroles and imidazoles as bet protein inhibitors

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3610848A1 (de) * 1986-04-01 1987-10-15 Boehringer Ingelheim Kg Neue 1,4-diazepine
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
EP0638560A4 (en) 1991-10-11 1995-03-29 Yoshitomi Pharmaceutical MEDICINE FOR OSTEOPOROSIS AND DIAZEPINE COMPOUND *.
JPH06128257A (ja) 1992-10-13 1994-05-10 Yoshitomi Pharmaceut Ind Ltd ピリドジアゼピン化合物
CA2176020A1 (en) 1993-11-22 1995-06-01 John J. Baldwin Benzodiazepines
IT1285567B1 (it) 1996-02-21 1998-06-18 Alfa Chem Ital Nuovo processo per la sintesi del nabumetone
CN1227555A (zh) * 1996-06-12 1999-09-01 日本烟草产业株式会社 细胞因子生成抑制剂、三氮䓬化合物及其中间体
DK0989131T3 (da) 1996-09-13 2003-03-03 Mitsubishi Pharma Corp Thienotriazolodiazepinforbindelser og deres medicinske anvendelse
JPH11228576A (ja) * 1997-12-10 1999-08-24 Japan Tobacco Inc アポトーシス抑制剤
WO2005044354A1 (en) 2003-11-03 2005-05-19 Glaxo Group Limited A fluid dispensing device
US7223733B2 (en) 2004-03-31 2007-05-29 National University Of Singapore Modulation of TRIP-Br function and method of treating proliferative disorders
GB0420970D0 (en) 2004-09-21 2004-10-20 Smithkline Beecham Corp Novel triazoloquinoline compounds
TWI447120B (zh) 2005-05-30 2014-08-01 Mitsubishi Tanabe Pharma Corp 噻吩并三唑并苯二氮呯化合物、其醫藥上之用途
JP2008156311A (ja) 2006-12-26 2008-07-10 Institute Of Physical & Chemical Research Ｂｒｄ２ブロモドメイン結合剤
EP2239264A4 (en) 2007-12-28 2012-01-11 Mitsubishi Tanabe Pharma Corp ANTITUMOR AGENT
GB0919431D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds

Also Published As

Publication number Publication date
HK1175458A1 (en) 2013-07-05
JP2013510107A (ja) 2013-03-21
US20120220573A1 (en) 2012-08-30
AU2010314395A1 (en) 2012-05-24
HUE026421T2 (en) 2016-05-30
IL235983B (en) 2018-01-31
CL2012001178A1 (es) 2012-10-05
DK2722334T3 (en) 2016-03-07
IL235983A0 (en) 2015-01-29
CN102762569B (zh) 2015-04-01
ME02360B (me) 2016-06-20
EP3037423B1 (en) 2017-09-20
EP3037423A1 (en) 2016-06-29
RS53179B (en) 2014-06-30
US20170197972A1 (en) 2017-07-13
EP2722334B1 (en) 2016-01-13
BR112012010706A2 (pt) 2016-03-29
RS54592B1 (en) 2016-08-31
CR20120283A (es) 2012-08-14
CO6540003A2 (es) 2012-10-16
EP2496580A1 (en) 2012-09-12
ES2446647T3 (es) 2014-03-10
NZ599258A (en) 2014-05-30
PT2722334E (pt) 2016-03-11
KR101424989B1 (ko) 2014-07-31
JP5524343B2 (ja) 2014-06-18
SI2496580T1 (sl) 2014-02-28
EA201290183A1 (ru) 2012-12-28
MA33803B1 (fr) 2012-12-03
PL2496580T3 (pl) 2014-06-30
CA2779355A1 (en) 2011-05-12
AU2010314395B2 (en) 2015-04-09
CA2779355C (en) 2018-01-16
EP2722334A1 (en) 2014-04-23
MX2012005295A (es) 2012-06-19
PL2722334T3 (pl) 2016-06-30
CY1114988T1 (el) 2016-12-14
US20150210706A1 (en) 2015-07-30
SMT201400024B (it) 2014-07-07
KR20120099250A (ko) 2012-09-07
MY160456A (en) 2017-03-15
ES2563057T3 (es) 2016-03-10
IL219090A0 (en) 2012-06-28
HK1220188A1 (zh) 2017-04-28
HRP20140107T1 (hr) 2014-04-25
WO2011054553A1 (en) 2011-05-12
EP2496580B1 (en) 2013-12-11
DK2496580T3 (da) 2014-02-24
HK1191012A1 (zh) 2014-07-18
HRP20160119T1 (hr) 2016-02-26
ES2652304T3 (es) 2018-02-01
DOP2012000114A (es) 2012-08-15
EA020390B1 (ru) 2014-10-30
PE20121181A1 (es) 2012-09-13
CY1117479T1 (el) 2017-04-26
SI2722334T1 (sl) 2016-03-31
US9023842B2 (en) 2015-05-05
CN102762569A (zh) 2012-10-31
SMT201600081B (it) 2016-04-29

Similar Documents

Publication Publication Date Title
HK1221221A1 (zh) 苯並二氮雜䓬溴結構域抑制劑
IL235983A0 (en) A benzodiazepine bromodomain inhibitor
ZA201105352B (en) Novel benzodiazepine derivatives
HK1139235A1 (en) Transformer system
PL2285329T3 (pl) Tampon
GB0901898D0 (en) Dual calpain-ros inhibitors
ZA201102837B (en) Phosphodiestarase inhibitors
GB2462291B (en) Multi-toroid transformer
GB0901900D0 (en) Dual calpain-ros inhibitors
GB2458457B (en) Transformer
GB2460334B (en) Transformer
GB0902661D0 (en) Inhibitors
GB0903650D0 (en) Glyoalase inhibitors
EP2462942A4 (en) PLASMA PROTEIN WITH A HUSTENING LIGHTING EFFECT
GB0803891D0 (en) Glyoxalase inhibitors
GB201019387D0 (en) Inhibitors
AU323408S (en) Tampon
AU323411S (en) Tampon
AU323410S (en) Tampon
AU323409S (en) Tampon
AU323407S (en) Tampon
AU323406S (en) Tampon
AU323412S (en) Tampon